Consainsights logo

Congenital Heart Disease Market Size, Share, Industry Trends and Forecast to 2030

Congenital Heart Disease Market Research Report – Segmented By Region (North America, Europe, Asia-Pacific, Middle-East & Africa, Latin America) – Analysis on Size, Share, Trends, COVID-19 Impact, Competitive Analysis, Growth Opportunities and Key Insights from 2019 to 2030.

  • Published date -30th Jan 2024

  • Formats -PDF, CSV

  • Region -Global

Congenital Heart Disease Market Size & CAGR in 2021

The global congenital heart disease market is estimated to have a Compound Annual Growth Rate (CAGR) of 4.5% in 2021. The market size is expected to reach USD 8.7 billion by the end of the year.

COVID-19 Impact on the Congenital Heart Disease Market

The outbreak of COVID-19 has significantly impacted the congenital heart disease market. Due to the pandemic, many hospitals and healthcare facilities had to prioritize resources for COVID-19 patients, leading to delays in non-emergency procedures for congenital heart disease patients. This has resulted in a decline in the diagnosis and treatment of congenital heart diseases. However, the market is expected to recover as healthcare services resume normal operations.

Congenital Heart Disease Dynamics

Congenital heart disease refers to structural abnormalities of the heart that are present at birth. These abnormalities can affect the heart's valves, chambers, or blood vessels. The market for congenital heart disease is driven by factors such as increasing prevalence of congenital heart diseases, advancements in medical technology for diagnosis and treatment, and growing awareness about early detection and intervention.

Segments and Related Analysis

The congenital heart disease market can be segmented based on the type of defect, age group, and treatment methods. Common types of congenital heart defects include atrial septal defect, ventricular septal defect, and tetralogy of Fallot. Treatment options range from medications to surgical interventions, depending on the severity of the defect.

By Region Analysis

The congenital heart disease market varies by region due to factors such as healthcare infrastructure, access to specialized care, and prevalence of risk factors. North America and Europe are the leading regions for congenital heart disease treatment, while emerging markets in Asia Pacific and Latin America are expected to show significant growth in the coming years.

Key Market Players and Competitive Landscape

Key players in the congenital heart disease market include Medtronic, Abbott Laboratories, Edwards Lifesciences, Boston Scientific Corporation, and LivaNova. These companies offer a range of products and services for the diagnosis and treatment of congenital heart diseases, contributing to a competitive landscape in the market.

Recent Happenings in the Congenital Heart Disease Market

- In January 2021, Medtronic received FDA approval for its Melody Transcatheter Pulmonary Valve, a minimally invasive treatment option for congenital heart disease patients.

- In March 2021, Abbott Laboratories announced the launch of its Amplatzer Piccolo Occluder, a device for the treatment of patent ductus arteriosus in premature infants with congenital heart defects.

- In May 2021, Edwards Lifesciences introduced its PASCAL System for transcatheter mitral valve repair, offering a non-surgical option for patients with congenital heart diseases.

These developments highlight the ongoing innovation and advancements in the congenital heart disease market, aimed at improving outcomes for patients with congenital heart defects.